{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:52:53Z","timestamp":1781455973889,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtha.2025.09.043","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:16:49Z","timestamp":1761959809000},"page":"866-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antithrombosis stewardship across the care spectrum: optimizing transitions in venous thromboembolism"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-4975","authenticated-orcid":false,"given":"Allison E.","family":"Burnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara K.","family":"Lech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Silvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.09.043_bib1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/ATVBAHA.124.320151","article-title":"Global health burden of venous thromboembolism","volume":"44","author":"Wendelboe","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.09.043_bib2","first-page":"e41","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.09.043_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.7326\/M23-2442","article-title":"Trends in discharge rates for acute pulmonary embolism in U.S. emergency departments","volume":"177","author":"Watson","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.09.043_bib4","first-page":"239","article-title":"The risk of incident venous thromboembolism attributed to overweight and obesity: the Troms\u00f8 study","volume":"124","author":"Frischmuth","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib5","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.09.043_bib6","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.09.043_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2022.100125","article-title":"Advancing anticoagulation stewardship: a call to action for stewardship from the US-based anticoagulation forum","volume":"9","author":"Burnett","year":"2022","journal-title":"Thromb Update"},{"key":"10.1016\/j.jtha.2025.09.043_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2023.100158","article-title":"Value of hospital anticoagulation stewardship programme: a systematic review","volume":"14","author":"Silvari","year":"2024","journal-title":"Thromb Update"},{"key":"10.1016\/j.jtha.2025.09.043_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.09.043_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109335","article-title":"Letter-to-the-editor: long-term outcomes of patients with isolated subsegmental pulmonary embolism managed without anticoagulant therapy","volume":"250","author":"Brown","year":"2025","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.043_bib11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1177\/00031348231220586","article-title":"Clinical surveillance vs anticoagulation therapy for isolated subsegmental pulmonary embolism: a systematic review of clinical outcomes","volume":"90","author":"Chin","year":"2024","journal-title":"Am Surg"},{"key":"10.1016\/j.jtha.2025.09.043_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5114\/aoms\/99206","article-title":"Safety, efficacy, length of stay and patient satisfaction with outpatient management of low-risk pulmonary embolism patients\u2014a meta-analysis","volume":"17","author":"Malik","year":"2021","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jtha.2025.09.043_bib13","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1016\/j.jtha.2024.09.019","article-title":"JTH in clinic: management of low-risk pulmonary embolism","volume":"22","author":"Han","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.thromres.2013.08.003","article-title":"Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials","volume":"132","author":"Limone","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.043_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.thromres.2022.01.007","article-title":"Clinical characteristics, time course, and outcomes of major bleeding according to bleeding site in patients with venous thromboembolism","volume":"211","author":"Bikdeli","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.043_bib16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/17085381211020969","article-title":"High incidence of patients lost to follow-up after venous thromboembolism diagnosis\u2014identifying an unmet need for targeted transition of care","volume":"30","author":"Rokosh","year":"2022","journal-title":"Vascular"},{"key":"10.1016\/j.jtha.2025.09.043_bib17","author":"Beresford"},{"key":"10.1016\/j.jtha.2025.09.043_bib18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","article-title":"Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment","volume":"41","author":"Burnett","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.09.043_bib19","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1093\/ajhp\/zxaf024","article-title":"Considerations in educating patients receiving oral anticoagulation: quality over quantity","volume":"82","author":"Dager","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2025.09.043_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31973","article-title":"Assessment of an intervention to reduce aspirin prescribing for patients receiving warfarin for anticoagulation","volume":"5","author":"Schaefer","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2025.09.043_bib21","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.09.043_bib22","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.09.043_bib23","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.5207","article-title":"Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.09.043_bib24","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.09.043_bib25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","article-title":"Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease","volume":"85","author":"Rashedi","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.09.043_bib26","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","article-title":"Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation","volume":"23","author":"Lemesle","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.043_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4140\/TCP.n.2024.212","article-title":"Pharmacist-led deprescribing of aspirin in older people in an outpatient setting","volume":"39","author":"Ramos","year":"2024","journal-title":"Sr Care Pharm"},{"key":"10.1016\/j.jtha.2025.09.043_bib28","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.09.043_bib29","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood.2023021638","article-title":"How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both?","volume":"143","author":"May","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.043_bib30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.09.043_bib31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.14309\/ajg.0000000000000558","article-title":"Physicians\u2019 perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey","volume":"115","author":"Kurlander","year":"2020","journal-title":"J Am Coll Gastroenterol"},{"key":"10.1016\/j.jtha.2025.09.043_bib32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/a-2173-7729","article-title":"Recurrent venous thromboembolism in patients on anticoagulation: an update based on the revised AWMF S2k guideline","volume":"44","author":"Klamroth","year":"2024","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.jtha.2025.09.043_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.thromres.2019.06.017","article-title":"Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?","volume":"180","author":"Rodger","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.043_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor\u2019s choice\u2014European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jtha.2025.09.043_bib35","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jth.12301","article-title":"The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH","volume":"11","author":"Ageno","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib36","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1538-7836.2011.04240.x","article-title":"Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study","volume":"9","author":"Le Gal","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib37","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/j.1538-7836.2011.04533.x","article-title":"Baseline imaging after therapy for unprovoked venous thromboembolism: a randomized controlled comparison of baseline imaging for diagnosis of suspected recurrence","volume":"9","author":"Hamadah","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib38","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.3390\/jcm12185955","article-title":"Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios","volume":"12","author":"Luc\u00e0","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.09.043_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.007971","article-title":"Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis","volume":"14","author":"Zhang","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jtha.2025.09.043_bib40","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jtha.2025.02.026","article-title":"How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"23","author":"Gendron","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib41","unstructured":"Castelluci LA. Comparison of bleeding risk between rivaroxaban and apixaban in acute VTE: The COBRRA trial. Presented at the 33rd International Society on Thrombosis and Haemostasis Congress, June 22, 2025."},{"key":"10.1016\/j.jtha.2025.09.043_bib42","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025471","article-title":"Length of anticoagulation in provoked venous thromboembolism: a multicenter study of how real-world practice mirrors guideline recommendations","volume":"11","author":"Joyce","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.09.043_bib43","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/jth.14535","article-title":"Risk prediction of recurrent venous thrombosis; where are we now and what can we add?","volume":"17","author":"Timp","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib44","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1055\/s-0041-1729171","article-title":"Prediction of major bleeding in anticoagulated patients for venous thromboembolism: comparison of the RIETE and the VTE-BLEED scores","volume":"5","author":"Lecumberri","year":"2021","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2025.09.043_bib45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.jtha.2025.09.043_bib46","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1160\/TH16-10-0810","article-title":"External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism","volume":"117","author":"Klok","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib47","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/jth.14156","article-title":"Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis","volume":"16","author":"Vasanthamohan","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.043_bib48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.043_bib49","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMoa2509426","article-title":"Apixaban for extended treatment of provoked venous thromboembolism","volume":"393","author":"Piazza","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.043_bib50","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:02:59Z","timestamp":1781452979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625006750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1538783625006750"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.043","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombosis stewardship across the care spectrum: optimizing transitions in venous thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}